Top Ventricular Assist Devices Companies

Ventricular Assist Devices Market size was valued at USD 2.59 Billion in 2024 and is poised to grow from USD 2.79 Billion in 2025 to USD 5.13 Billion by 2033, growing at a CAGR of 7.9% during the forecast period (2026–2033).

Investing in the development of affordable and easy to use ventricular assist devices will be the prime focus of all ventricular assist device companies. Use of advanced technologies and growing emphasis on increasing awareness regarding the benefits of the use of ventricular assist devices will also create new opportunities for market players. Collaborations and partnerships will also play a crucial role in augmenting the future of all ventricular assist device suppliers. 'TELEFLEX INCORPORATED ', 'Abbott ', 'Berlin Heart ', 'Cardiac Assist, Inc. ', 'Jarvik Heart, Inc. ', 'ReliantHeart, Inc. ', 'SYNCARDIA SYSTEMS ', 'FRESENIUS MEDICAL CARE AG & CO. KGAA ', 'GETINGE ', 'SENKO MEDICAL INSTRUMENT MFG. CO., LTD ', 'ANGIODROID ', 'CARDIODYME ', 'WORLD HEART CORPORATION ', 'Sun Medical Technology Research Corp ', 'FineHeart SA ', 'BiVACOR  ', 'CorWave SA ', 'Windmill Cardiovascular Systems ', 'Leviticus Cardio ', 'CardioBridge GmbH'

Ventricular assist devices have gained substantial attention and popularity in recent years, and this is estimated to favor market growth over the coming years. As patients become more aware of the benefits associated with ventricular assist devices, they are more likely to opt for them to improve their chances of treatment going forward.

Miniaturization of Ventricular Assist Devices: Companies of ventricular assist devices should focus on making their offerings smaller to improve their scope of implantation and thereby boost sales as well. Use of miniaturized components coupled with innovations in design could very well help ventricular assist devices market players achieve this and stand out in the global landscape.

North America is expected to spearhead the global demand for ventricular assist devices across the study period. High healthcare expenditure and availability of advanced ventricular assist devices are primarily helping this region maintain its dominant stance in the global landscape. High availability of favorable reimbursement policies, growing incidence of cardiovascular disorders, rising obesity rates, and expanding geriatric population are other factors that could uplift sales of ventricular assist devices in this region. Canada and the United States are anticipated to be the most opportune markets for ventricular assist device companies in the North American region going forward.